- Business Wire•4 months ago
Prana Biotechnology Ltd is pleased to announce that further analysis of the cognitive results of its Reach2HD trial to treat Huntington Disease was presented in a poster1 at the American Neurological Association Annual Meeting in Baltimore, United States.
- Business Wire•7 months ago
Professor Rudolph Tanzi, Founding Scientist and Chief Scientific Advisor for Prana Biotechnology, presented results obtained from testing PBT2, Prana’s lead candidate for Huntington and Alzheimer’s diseases, at the Alzheimer’s Association International Conference in Toronto, Canada on July 26, 2016.
- Insider Monkey•8 months ago
The US stock market is mixed, but relatively flat on Wednesday, following Federal Reserve Chairwoman Janet Yellen’s dovish message on interest rates, and ahead of tomorrow’s Brexit vote, which now seems like it will resolve toward a “Stay”. Among individual stocks, Prana Biotechnology Limited (ADR) (NASDAQ:PRAN), Michael Kors Holdings Ltd (NYSE:KORS), Advanced Micro Devices, Inc. […]
PBT.AX : Summary for PRANA FPO - Yahoo Finance
Prana Biotechnology Limited (PBT.AX)
ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
|Day's Range||0.05 - 0.05|
|52 Week Range||0.04 - 0.15|
|PE Ratio (TTM)||-3.64|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|